AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
Cancer stem cells (CSCs) play a crucial role in tumor initiation, recurrence, metastasis, and drug resistance. However, the current understanding of CSCs in hepatocellular carcinoma (HCC) remains incomplete. Through a comprehensive analysis of the database, it has been observed that 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), a critical enzyme involved in cholesterol synthesis, is up-regulated in HCC tissues and liver CSCs. Moreover, high expression of HMGCR is associated with a poor prognosis in patients with HCC. Functionally, HMGCR promotes the stemness and metastasis of HCC both in vitro and in vivo. By screening various signaling pathway inhibitors, we have determined that HMGCR regulates stemness and metastasis by activating the Hedgehog signaling in HCC. Mechanistically, HMGCR positively correlates with the expression of the Smoothened receptor and facilitates the nuclear translocation of the transcriptional activator GLI family zinc finger 1. Inhibition of the Hedgehog pathway can reverse the stimulatory effects of HMGCR on stemness and metastasis in HCC. Notably, simvastatin, an FDA-approved cholesterol-lowering drug, has been shown to inhibit stemness and metastasis of HCC by targeting HMGCR. Taken together, our findings suggest that HMGCR promotes the regeneration and metastasis of HCC through the activation of Hedgehog signaling, and simvastatin holds the potential for clinical suppression of HCC metastasis.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209-249.
Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345-1362.
An X, Li F, Mou C, Li D. A systematic review and meta-analysis on prognosis and survival of hepatocellular carcinoma with lung metastasis after hepatectomy. Ann Palliat Med. 2021;10(8):9039-9048.
Yang C, Zhang H, Zhang L, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20(4):203-222.
Nevola R, Ruocco R, Criscuolo L, et al. Predictors of early and late hepatocellular carcinoma recurrence. World J Gastroenterol. 2023;29(8):1243-1260.
Saraiya N, Yopp AC, Rich NE, Odewole M, Parikh ND, Singal AG. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018;48(2):127-137.
Saygin C, Matei D, Majeti R, Reizes O, Lathia JD. Targeting cancer stemness in the clinic: from hype to hope. Cell Stem Cell. 2019;24(1):25-40.
Liu YC, Yeh CT, Lin KH. Cancer stem cell functions in hepatocellular carcinoma and comprehensive therapeutic strategies. Cells. 2020;9(6):1331.
Pradella D, Naro C, Sette C, Ghigna C. EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression. Mol Cancer. 2017;16(1):8.
Huang B, Song BL, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2(2):132-141.
Che L, Chi W, Qiao Y, et al. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut. 2020;69(1):177-186.
Xu H, Zhou S, Tang Q, Xia H, Bi F. Cholesterol metabolism: new functions and therapeutic approaches in cancer. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188394.
Kim HY, Bae SJ, Choi JW, et al. Cholesterol synthesis is important for breast cancer cell tumor sphere formation and invasion. Biomedicines. 2022;10(8):1908.
Gao S, Soares F, Wang S, et al. CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer. Oncogene. 2021;40(48):6601-6613.
Yang L, Sun J, Li M, et al. Oxidized low-density lipoprotein links hypercholesterolemia and bladder cancer aggressiveness by promoting cancer stemness. Cancer Res. 2021;81(22):5720-5732.
Liu C, Chen H, Hu B, Shi J, Chen Y, Huang K. New insights into the therapeutic potentials of statins in cancer. Front Pharmacol. 2023;14:1188926.
Jiang W, Hu JW, He XR, Jin WL, He XY. Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res. 2021;40(1):241.
Tuo L, Xiang J, Pan X, et al. PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis. J Exp Clin Cancer Res. 2019;38(1):50.
Gou D, Liu R, Shan X, et al. Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression. J Clin Invest. 2023;133(13):e161713.
Xu FL, Wu XH, Chen C, et al. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase. Cell Death Dis. 2023;14(1):22.
Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol. 2016;9(1):74.
Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212-226.
Ding J, Li HY, Zhang L, Zhou Y, Wu J. Hedgehog signaling, a critical pathway governing the development and progression of hepatocellular carcinoma. Cells. 2021;10(1):123.
Fan YH, Ding J, Nguyen S, et al. Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells. Oncogene. 2016;35(1):116-124.
Liu CH, Lan CT, Chou JF, Tseng TJ, Liao WC. CHSY1 promotes aggressive phenotypes of hepatocellular carcinoma cells via activation of the hedgehog signaling pathway. Cancer Lett. 2017;403:280-288.
Li C, Wu W, Xie K, Feng Y, Xie N, Chen X. HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells. Gene. 2016;587(1):42-47.
Radhakrishnan A, Rohatgi R, Siebold C. Cholesterol access in cellular membranes controls Hedgehog signaling. Nat Chem Biol. 2020;16(12):1303-1313.
Kaushal JB, Batra SK, Rachagani S. Hedgehog signaling and its molecular perspective with cholesterol: a comprehensive review. Cell Mol Life Sci. 2022;79(5):266.
Deshpande G, Godishala A, Schedl P. Ggamma1, a downstream target for the hmgcr-isoprenoid biosynthetic pathway, is required for releasing the Hedgehog ligand and directing germ cell migration. PLoS Genet. 2009;5(1):e1000333.
Zhou W, Liu H, Yuan Z, et al. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell. 2023;41(4):740-756.e10.
Guo C, Wan R, He Y, et al. Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer. Nat Can (Ott). 2022;3(5):614-628.
Liang J, Yu D, Luo C, et al. Epigenetic suppression of PGC1α (PPARGC1A) causes collateral sensitivity to HMGCR-inhibitors within BRAF-treatment resistant melanomas. Nat Commun. 2023;14(1):3251.
Rao Y, Samuels Z, Carter LM, et al. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers. Proc Natl Acad Sci USA. 2023;120(14):e2220413120.
Nam GH, Kwon M, Jung H, et al. Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. J Immunother Canc. 2021;9(7):e002474.
Sun SJ, Ai YJ, Duan KL, et al. TET2 deficiency sensitizes tumor cells to statins by reducing HMGCS1 expression. Oncogene. 2022;41(50):5385-5396.
Majidi A, Na R, Jordan SJ, De Fazio A, Webb PM, Study Group OPAL. Statin use and survival following a diagnosis of ovarian cancer: a prospective observational study. Int J Cancer. 2021;148(7):1608-1615.
Kim DS, Ahn HS, Kim HJ. Statin use and incidence and mortality of breast and gynecology cancer: a cohort study using the National Health Insurance claims database. Int J Cancer. 2022;150(7):1156-1165.
Pourlotfi A, Ahl Hulme R, Forssten MP, et al. Statin therapy and its association with long-term survival after colon cancer surgery. Surgery. 2022;171(4):890-896.
Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2013;368(6):576-577.
Allott EH, Ebot EM, Stopsack KH, et al. Statin use is associated with lower risk of PTEN-null and lethal prostate cancer. Clin Cancer Res. 2020;26(5):1086-1093.
Kansal V, Burnham AJ, Kinney BLC, et al. Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. J Immunother Canc. 2023;11(1):e005940.
Gohlke BO, Zincke F, Eckert A, et al. Real-world evidence for preventive effects of statins on cancer incidence: a trans-Atlantic analysis. Clin Transl Med. 2022;12(2):e726.
Zhang Y, Wu K, Chan AT, Meyerhardt JA, Giovannucci EL. Long-term statin use, total cholesterol level, and risk of colorectal cancer: a prospective cohort study. Am J Gastroenterol. 2022;117(1):158-166.
Koohestanimobarhan S, Salami S, Imeni V, Mohammadi Z, Bayat O. Lipophilic statins antagonistically alter the major epithelial-to-mesenchymal transition signaling pathways in breast cancer stem-like cells via inhibition of the mevalonate pathway. J Cell Biochem. 2019;120(2):2515-2531.
Kato S, Liberona MF, Cerda-Infante J, et al. Simvastatin interferes with cancer 'stem-cell' plasticity reducing metastasis in ovarian cancer. Endocr Relat Cancer. 2018;25(10):821-836.
Yin Y, Liu L, Zhao Z, et al. Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer. Cancer Lett. 2018;426:14-24.
Vell MS, Loomba R, Krishnan A, et al. Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality. JAMA Netw Open. 2023;6(6):e2320222.
Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study. J Hepatol. 2018;68(3):476-484.
Jeon D, Cha HR, Chung SW, et al. Association between statin use and the prognosis of hepatocellular carcinoma after resection: a nationwide cohort study. EClinicalMedicine. 2023;65:102300.
Göbel A, Breining D, Rauner M, Hofbauer LC, Rachner TD. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Cell Death Dis. 2019;10(2):91.
Longo J, Pandyra AA, Stachura P, Minden MD, Schimmer AD, Penn LZ. Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. Mol Oncol. 2020;14(10):2533-2545.
Dorsch M, Kowalczyk M, Planque M, et al. Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis. Cell Rep. 2021;37(8):110056.
Kafka M, Gruber R, Neuwirt H, Ladurner M, Eder IE. Long-term treatment with simvastatin leads to reduced migration capacity of prostate cancer cells. Biomedicines. 2022;11(1):29.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
京公网安备11010802044758号